INT27446

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1980
Last Reported 2010
Negated 0
Speculated 1
Reported most in Abstract
Documents 11
Total Number 13
Disease Relevance 5.58
Pain Relevance 3.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (CTSA) mitochondrion (CTSA) small molecule metabolic process (CTSA)
endoplasmic reticulum (CTSA) nucleolus (CTSA) nucleus (CTSA)
Anatomy Link Frequency
leukocyte 3
platelet 2
photoreceptor 1
cornea 1
CTSA (Homo sapiens)
Pain Link Frequency Relevance Heat
aspirin 9 100.00 Very High Very High Very High
metalloproteinase 6 100.00 Very High Very High Very High
cINOD 23 99.76 Very High Very High Very High
diclofenac 3 99.20 Very High Very High Very High
rheumatoid arthritis 2 96.28 Very High Very High Very High
Inflammation 5 95.72 Very High Very High Very High
cva 12 89.12 High High
dexamethasone 3 85.28 High High
Neuropathic pain 3 75.20 Quite High
Hyperesthesia 1 72.56 Quite High
Disease Link Frequency Relevance Heat
Lysosomal Storage Diseases 1 99.74 Very High Very High Very High
INFLAMMATION 22 99.56 Very High Very High Very High
Age-related Macular Degeneration 38 99.20 Very High Very High Very High
Corneal Disease 46 98.86 Very High Very High Very High
Disorders Of Galactose Metabolism 4 98.44 Very High Very High Very High
Rheumatoid Arthritis 2 96.28 Very High Very High Very High
Gauchers Disease 62 95.84 Very High Very High Very High
Death 4 90.52 High High
Disease 23 90.08 High High
Hemorrhage 12 89.12 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Acetylsalicylic acid added to platelet lysate inhibited cathepsin A in the same extent as salicylate.
Negative_regulation (inhibited) of cathepsin A in platelet associated with aspirin
1) Confidence 0.57 Published 1996 Journal Pol J Pharmacol Section Abstract Doc Link 9112639 Disease Relevance 0.25 Pain Relevance 0.44
Indomethacin, phenacetin and aminophenazone were the most potent inhibitors of cathepsin A.
Negative_regulation (inhibitors) of cathepsin A
2) Confidence 0.57 Published 1996 Journal Pol J Pharmacol Section Abstract Doc Link 9112639 Disease Relevance 0.26 Pain Relevance 0.45
Galactosialidosis (MIM 256540) is an autosomal recessive lysosomal storage disease caused by a defect of the protective protein/cathepsin A.
Negative_regulation (defect) of cathepsin A associated with disorders of galactose metabolism and lysosomal storage diseases
3) Confidence 0.42 Published 2009 Journal Eur. J. Paediatr. Neurol. Section Abstract Doc Link 19097920 Disease Relevance 0.64 Pain Relevance 0.22
Inhibition of human platelet cathepsin A by non-steroidal anti-inflammatory drugs--in vitro study.
Negative_regulation (Inhibition) of cathepsin A in platelet associated with aspirin, inflammation and cinod
4) Confidence 0.42 Published 1996 Journal Pol J Pharmacol Section Title Doc Link 9112639 Disease Relevance 0.29 Pain Relevance 0.52
Phenylbutazone, oxyphenbutazone, sulfinpyrazone and diclofenac-sodium proved to be the most efficient inhibitors of elastase and cathepsin G.
Negative_regulation (inhibitors) of cathepsin associated with diclofenac
5) Confidence 0.40 Published 1989 Journal Arzneimittelforschung Section Abstract Doc Link 2610712 Disease Relevance 0.25 Pain Relevance 0.31
20 non-steroidal anti-inflammatory drugs and other agents were evaluated for their effectiveness in directly inhibiting the proteolytic activity of human leukocyte elastase and cathepsin G.
Negative_regulation (inhibiting) of cathepsin in leukocyte associated with inflammation and cinod
6) Confidence 0.38 Published 1980 Journal Arzneimittelforschung Section Abstract Doc Link 6908533 Disease Relevance 0.17 Pain Relevance 0.17
Inhibition of human leukocyte elastase and cathepsin G by anti-inflammatory drugs.
Negative_regulation (Inhibition) of cathepsin in leukocyte associated with inflammation and cinod
7) Confidence 0.38 Published 1980 Journal Arzneimittelforschung Section Title Doc Link 6908533 Disease Relevance 0.20 Pain Relevance 0.20
Furthermore, alterations in the genes encoding tissue inhibitor of metalloproteinase 3 (TIMP-3) and cathepsin are also found in a cornea with keratoconus [14,15].
Negative_regulation (inhibitor) of cathepsin in cornea associated with corneal disease and metalloproteinase
8) Confidence 0.35 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2843708 Disease Relevance 1.14 Pain Relevance 0.08
Thus the leukocyte extract containing the partially purified elastase and cathepsin G which can be rapidly and easily prepared at low costs appears to be an efficient mean of screening potentially new therapeutic agents for their ability to inhibit leukocyte elastase and cathepsin G.
Negative_regulation (inhibit) of cathepsin in leukocyte
9) Confidence 0.26 Published 1996 Journal Inflamm. Res. Section Abstract Doc Link 8841833 Disease Relevance 0.13 Pain Relevance 0.24
The aim of our study was to examine whether anti-inflammatory drugs and selected compounds inhibited elastase and cathepsin G, and also to determine whether it is necessary to use a highly purified elastase preparation to screen drugs for their ability to block the activity of this enzyme.
Spec (whether) Negative_regulation (inhibited) of cathepsin associated with inflammation and cinod
10) Confidence 0.26 Published 1996 Journal Inflamm. Res. Section Abstract Doc Link 8841833 Disease Relevance 0.32 Pain Relevance 0.35
Cathepsin, which contributes to the initiation and/or progression of keratoconus, is also responsible for photoreceptor homeostasis, and deregulation of cathepsin is associated with macular degeneration [15].
Negative_regulation (deregulation) of cathepsin in photoreceptor associated with corneal disease and age-related macular degeneration
11) Confidence 0.25 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2843708 Disease Relevance 1.43 Pain Relevance 0.09
Several animal studies also showed that depletion of GSL could be lethal or lead to neurological disturbance, and substrate reduction therapy should be aimed to reduce biosynthesis of GSL to a degree that can be tolerated by cells (Radin 1996).
Negative_regulation (depletion) of GSL
12) Confidence 0.15 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504062 Disease Relevance 0.15 Pain Relevance 0
A partial increase in enzyme activity may be sufficient to initiate the metabolic breakdown of glycosphyngolipids (GSL) and decrease the GSL storage in lysosomes.
Negative_regulation (decrease) of GSL
13) Confidence 0.13 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504062 Disease Relevance 0.34 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox